Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7374-7379

  Soverini, Simona ^a   Colarossi, Sabrina ^a   Gnani, Alessandra ^a   Rosti, Gianantonio ^a   Castagnetti, Fausto ^a   Poerio, Angela ^a   Iacobucci, Ilaria ^a   Amabile, Marilina ^a   Abruzzese, Elisabetta ^b   Orlandi, Ester ^c   Radaelli, Franca ^d   Ciccone, Fabrizio ^e   Tiribelli, Mario ^f   Di Lorenzo, Roberto ^g   Caracciolo, Clementina ^h   Izzo, Barbara ⁱ   Pane, Fabrizio ⁱ   Saglio, Giuseppe ^j   Baccarani, Michele ^a   Martinelli, Giovanni ^a,k  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e Ospedale Civile   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g Ospedale Civile   (Italy)

^h Bone Marrow Transplantation Unit   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; IMATINIB;

ACUTE LYMPHOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC MYELOID LEUKEMIA; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MUTATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENE FREQUENCY; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PIPERAZINES; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES;

EID: 33846228789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1516     Document Type: Article

References (33)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myetogenous leukemia. N Engl J Med 2002; 346:645-52.
3. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99: 1928-37.
4. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study. Blood 2002;99:3530-9.
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
6. Cowan-Jacob SW, Guez V, Fendrich G, et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004;4:285-99.
7. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002;277: 32214-9.
8. Bohmer FD, Karagyozov L, Uecker A, et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem 2003;278:5148-55.
9. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
10. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI 571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
11. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
12. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
13. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359:487-91.
14. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 2002; 99:10700-5.
15. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99:1860-2.
16. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.
17. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
18. Al-Ali HK, Heinrich MC, Langet et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004;5:55-60.
19. Soverini S, Martinelli G, Rosti G, et al. Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005;23:4100-9.
20. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101: 4611-4.
21. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108:1809-20.
22. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
23. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86.
24. Soverini S, Martinelli G, Amabile M, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004;50:1205-13.
25. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112 831-43.
26. Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood 2005;106: 1133-4.
27. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-37.
28. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938-42.
29. Saraste M, Sibbald PR, Wittinghofer A. The P-loop - a common motif in ATP- and GTP-binding proteins. Trends Biochem Sci 1990;15:430-4.
30. Martinelli G, Soverini S, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 2005;19:1872-9.
31. Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun 2004; 319:1272-5.
32. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354: 2531-41.
33. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354: 2542-51.